InTouch Newsletter Issue 4
Congresses and Events
Three-year Results from the EVOLVE II Randomized Trial presented at ACC
Three-year follow-up from EVOLVE II trial presented by Dr. Dean Kereiakes supports longer-term safety and efficacy of the novel abluminal bioabsorbable polymer SYNERGY™ everolimus-eluting stent in a broad range of patients undergoing PCI.
Synergy™ BP Stent Launches 48mm Length
Long lesions represent a complex lesion subset that is associated with increased safety related events, reduced efficacy and increased procedure time. SYNERGY™ BP Stent was designed for quality healing and safety over time and with the addition of a 48mm length it has a complete size matrix to address these complex lesions.
Boston Scientific announces Agreement to acquire Symetis
Boston Scientific announced a definitive agreement to acquire Symetis SA. The Symetis portfolio includes the ACURATE TA™ and ACURATE neo/TF valve* systems for use in the treatment of high-risk patients suffering from severe and symptomatic aortic valve stenosis.
Educational Corner
EuroPCR LIVE case: Rotablation of LAD
Invasive physiological assessment can be used to guide revascularization of residual disease after PCI. From St. Thomas’ Hospital (London), a live demonstration of an optimal complete revascularization after primary PCI in patients with multivessel disease. Learn more about rotablation of LAD.
InCathlab Live Case: Right Coronary Artery CTO. Antegrade Recanalization
An innovative operation, the Antegrade Recanalization with Hybrid Approach, conducted with a live demonstration from London Chest Hospital by Dr. Elliot Smith and Dr. Simon Walsh.
GUIDEZILLA™: back-up support for calcified, complex and tortuous anatomy
“There is no way I would get two stents around two 90 degree turns without the support of the GUIDEZILLA™”, says Dr. Brian D. Arcement.
Clinical Studies
Early Discontinuation of Dual-Antiplatelet Therapy with SYNERGY™ Stents in High-Risk Patients Undergoing Complex PCI
As more elderly and co-morbid patients require percutaneous revascularization, 1 year of dual-antiplatelet therapy (DAPT) becomes concerning. SYNERGY™ stents allow for early cessation of DAPT.
Rotational atherectomy: You will never regret using it!
The contemporary RA technique aims to smoothen the lumen and disconnect the calcified coronary ring, thus leaving the way clear for further balloon dilatation and stent implantation. Dr. Teresa Strisciuglio and Dr. Emanuele Barbato illustrate the advantages deriving from the contemporary rotational atherectomy technique.
Synergy™ Stent: ST Rates from the Academic Research Consortium
According to the Academic Research Consortium, SYNERGY™ has demonstrated very low stent thrombosis rates across multiple clinical trials. Data in the table below show that Synergy™ Stent, with its abluminal and bioabsorbable polymer has reported consistently low sub-acute, late & very late ST in 18,000 patients across 9 studies.